What is a stock summary page? Click here for an overview.
Business Description

Cell Source Inc
NAICS : 325413
SIC : 2834
ISIN : US15114L1044
Description
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | -71.48 | |||||
Debt-to-Equity | -0.52 | |||||
Debt-to-EBITDA | -2.32 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 3.3 | |||||
3-Year EPS without NRI Growth Rate | 3.3 | |||||
3-Year FCF Growth Rate | 13.3 | |||||
3-Year Book Growth Rate | -17.1 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 68.11 | |||||
9-Day RSI | 58.99 | |||||
14-Day RSI | 54.29 | |||||
3-1 Month Momentum % | -27.41 | |||||
6-1 Month Momentum % | -2 | |||||
12-1 Month Momentum % | -46.55 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.01 | |||||
Quick Ratio | 0.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7 | |||||
Shareholder Yield % | -4.16 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -2142.1 | |||||
ROIC % | -37.18 | |||||
3-Year ROIIC % | -11.59 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -6.01 | |||||
EV-to-EBITDA | -6.01 | |||||
EV-to-FCF | -9.56 | |||||
Earnings Yield (Greenblatt) % | -16.64 | |||||
FCF Yield % | -16.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CLCS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cell Source Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.15 | ||
Beta | -239.41 | ||
3-Year Sharpe Ratio | 0.92 | ||
3-Year Sortino Ratio | 262.9 | ||
Volatility % | 49878.65 | ||
14-Day RSI | 54.29 | ||
14-Day ATR ($) | 0.05902 | ||
20-Day SMA ($) | 0.309797 | ||
12-1 Month Momentum % | -46.55 | ||
52-Week Range ($) | 0.0002 - 0.8401 | ||
Shares Outstanding (Mil) | 43.47 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cell Source Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cell Source Inc Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Cell Source Inc Frequently Asked Questions
What is Cell Source Inc(CLCS)'s stock price today?
The current price of CLCS is $0.36. The 52 week high of CLCS is $0.84 and 52 week low is $0.00.
When is next earnings date of Cell Source Inc(CLCS)?
The next earnings date of Cell Source Inc(CLCS) is .
Does Cell Source Inc(CLCS) pay dividends? If so, how much?
Cell Source Inc(CLCS) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |